KR20230019872A - 코로나바이러스 감염에 대한 중증 반응의 발생 위험을 평가하는 방법 - Google Patents

코로나바이러스 감염에 대한 중증 반응의 발생 위험을 평가하는 방법 Download PDF

Info

Publication number
KR20230019872A
KR20230019872A KR1020227045938A KR20227045938A KR20230019872A KR 20230019872 A KR20230019872 A KR 20230019872A KR 1020227045938 A KR1020227045938 A KR 1020227045938A KR 20227045938 A KR20227045938 A KR 20227045938A KR 20230019872 A KR20230019872 A KR 20230019872A
Authority
KR
South Korea
Prior art keywords
subject
risk
coefficient
human
assigned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227045938A
Other languages
English (en)
Korean (ko)
Inventor
질리안 수 다이트
니콜라스 마크 머피
리처드 올먼
Original Assignee
지네틱 테크놀로지스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901739A external-priority patent/AU2020901739A0/en
Application filed by 지네틱 테크놀로지스 리미티드 filed Critical 지네틱 테크놀로지스 리미티드
Publication of KR20230019872A publication Critical patent/KR20230019872A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Ecology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020227045938A 2020-05-27 2021-05-26 코로나바이러스 감염에 대한 중증 반응의 발생 위험을 평가하는 방법 Withdrawn KR20230019872A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2020901739 2020-05-27
AU2020901739A AU2020901739A0 (en) 2020-05-27 Methods of assessing risk of developing a severe response to Coronavirus infection
AU2020902052 2020-06-19
AU2020902052A AU2020902052A0 (en) 2020-06-19 Methods of assessing risk of developing a severe response to Coronavirus infection
AU2020903536 2020-09-30
AU2020903536A AU2020903536A0 (en) 2020-09-30 Methods of assessing risk of developing a severe response to coronavirus infection
AU2021900392A AU2021900392A0 (en) 2021-02-17 Methods of assessing risk of developing a severe response to Coronavirus infection
AU2021900392 2021-02-17
PCT/AU2021/050507 WO2021237292A1 (en) 2020-05-27 2021-05-26 Methods of assessing risk of developing a severe response to coronavirus infection

Publications (1)

Publication Number Publication Date
KR20230019872A true KR20230019872A (ko) 2023-02-09

Family

ID=78745661

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045938A Withdrawn KR20230019872A (ko) 2020-05-27 2021-05-26 코로나바이러스 감염에 대한 중증 반응의 발생 위험을 평가하는 방법

Country Status (10)

Country Link
US (2) US11257569B1 (https=)
EP (1) EP4158067A4 (https=)
JP (1) JP2023527834A (https=)
KR (1) KR20230019872A (https=)
CN (1) CN116134152A (https=)
AU (1) AU2021281702A1 (https=)
CA (1) CA3179313A1 (https=)
IL (1) IL298097A (https=)
MX (1) MX2022014931A (https=)
WO (1) WO2021237292A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023006518A (es) * 2020-12-03 2023-06-23 Regeneron Pharma Metodos de identificacion de sujetos que tienen un mayor riesgo de desarrollar una infeccion por coronavirus y su tratamiento.
US20230278029A1 (en) * 2022-03-01 2023-09-07 Dnanudge Limited Multiplex cartridge for detection of viral nucleic acids and human or animal snps
WO2023194369A1 (en) * 2022-04-08 2023-10-12 Fundació Institut Mar D'investigacions Mèdiques (Imim) Genetic markers for severe covid-19
CN117198517B (zh) * 2023-06-27 2024-04-30 安徽省立医院(中国科学技术大学附属第一医院) 基于机器学习的运动反应性评估和预测模型的建模方法
PL248077B1 (pl) * 2023-10-10 2025-10-13 Biolab Genetic Spolka Z Ograniczona Odpowiedzialnoscia Sposób określania poziomu ryzyka ciężkiego przebiegu choroby COVID-19 u pacjenta
PL249351B1 (pl) * 2023-10-10 2026-03-30 Biolab Genetic Spółka Z Ograniczoną Odpowiedzialnością Zestaw i sposób do określania metodą łańcuchowej reakcji polimerazy układu alleli w locus rs143334143 oraz rs74956615
CN121458076B (zh) * 2026-01-08 2026-04-03 山西唐讯科技有限公司 输电线可视化监测数据智能分析和预警方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5714330A (en) 1994-04-04 1998-02-03 Lynx Therapeutics, Inc. DNA sequencing by stepwise ligation and cleavage
US5695934A (en) 1994-10-13 1997-12-09 Lynx Therapeutics, Inc. Massively parallel sequencing of sorted polynucleotides
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
JP4540754B2 (ja) 1996-06-04 2010-09-08 ユニバーシティ オブ ユタ リサーチ ファウンデーション Ｐｃｒ中のハイブリダイゼーションのモニタリング
US6485944B1 (en) 1997-10-10 2002-11-26 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
US6511803B1 (en) 1997-10-10 2003-01-28 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
AU7537200A (en) 1999-09-29 2001-04-30 Solexa Ltd. Polynucleotide sequencing
US6898531B2 (en) 2001-09-05 2005-05-24 Perlegen Sciences, Inc. Algorithms for selection of primer pairs
US20030108919A1 (en) 2001-09-05 2003-06-12 Perlegen Sciences, Inc. Methods for amplification of nucleic acids
CA2513899C (en) 2003-01-29 2013-03-26 454 Corporation Methods of amplifying and sequencing nucleic acids
CN1768140B (zh) * 2003-03-24 2010-06-16 港大科桥有限公司 对引起严重急性呼吸道综合症(sars)的人病毒的高通量诊断性试验
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
EP2044221B1 (en) * 2006-07-21 2015-07-22 Epigenomics AG Methods and kit for analyses of methylation in colorectal cellular proliferative disorders
DK2438193T3 (en) * 2009-06-01 2015-10-19 Genetic Technologies Ltd Methods for assessing the risk of breast cancer
CA2962691C (en) * 2014-09-30 2023-05-23 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
US20200102617A1 (en) * 2017-01-24 2020-04-02 Genetic Technologies Limited Improved Methods For Assessing Risk of Developing Breast Cancer
US10643951B2 (en) * 2017-07-14 2020-05-05 Taiwan Semiconductor Manufacturing Co., Ltd. Mini identification mark in die-less region of semiconductor wafer
WO2021016391A1 (en) * 2019-07-23 2021-01-28 The Broad Institute, Inc. Health data aggregation and outbreak modeling
US20210340636A1 (en) * 2020-03-31 2021-11-04 Diasorin S.P.A. Assays for the Detection of SARS-CoV-2

Also Published As

Publication number Publication date
MX2022014931A (es) 2023-01-30
AU2021281702A1 (en) 2023-01-05
JP2023527834A (ja) 2023-06-30
CA3179313A1 (en) 2021-12-02
IL298097A (en) 2023-01-01
EP4158067A1 (en) 2023-04-05
US11257569B1 (en) 2022-02-22
WO2021237292A1 (en) 2021-12-02
US20220246242A1 (en) 2022-08-04
EP4158067A4 (en) 2024-09-25
CN116134152A (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
US11257569B1 (en) Methods of assessing risk of developing a severe response to coronavirus infection
JP2021035387A (ja) 遺伝子の変動の非侵襲的評価のための方法および処理
US10920279B2 (en) Method for modifying a treatment regimen of a human female subject
JP7126704B2 (ja) 結腸直腸癌発症のリスクを評価するための方法
US20200102617A1 (en) Improved Methods For Assessing Risk of Developing Breast Cancer
JP7485653B2 (ja) 移植片拒絶を検出する方法およびシステム
AU2022279367A1 (en) Methods of assessing risk of developing breast cancer
JP2023546240A (ja) 疾患を発症するリスクを評価する方法
JP7140707B2 (ja) 緑内障のリスクを判定する方法
JP2020174641A (ja) 加齢黄斑変性のリスクを判定する方法
WO2023102601A1 (en) Breast cancer risk assessment
WO2024008955A1 (en) Method of screening for severe covid-19 susceptibility
JP2020174638A (ja) 慢性中耳炎のリスクを判定する方法
JP2020178564A (ja) 慢性気管支炎のリスクを判定する方法
HK40001097A (en) Methods for assessing risk of developing colorectal cancer
HK40001097B (en) Methods for assessing risk of developing colorectal cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240527

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20250211

WITB Written withdrawal of application